Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07306949 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

Study acronym: ATTR-CM
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Interventions: Acolamidis (Drug) to Acoramidis (Drug) Study title revised · Eligibility criteria expanded, about 1 wordv2 Show 2 more changesShow less
    • Study title revised
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Amyloidosis
301 trials monitored
See 19 trials at risk
The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.
Trial Details
NCT Number NCT07306949
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions Transthyretin-type Cardiac Amyloidosis
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov